Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women. Of 727 KEEPS enrollees, 670 agreed to participate in this multicenter ancillary study. Women were 42 to 58 years old, within 36 months from last menstrual period. Data were collected from July 2005 through June 2008 and analyzed from July 2010 through June 2017. Interventions: Women were randomized to either 0.45 mg/d oral conjugated equine estrogens (o-CEE), 50 µg/d transdermal 17β-estradiol (t-E2), or placebo. Participants also received 200 mg oral micronized progesterone (if randomized to o-CEE or t-E2) or placebo (if randomized to placebo estrogens) for 12 days each month. Main Outcomes and Measures: Aspects of sexual function and experience (desire, arousal, lubrication, orgasm, satisfaction, and pain) were assessed using the Female Sexual Function Inventory (FSFI; range, 0-36 points; higher scores indicate better sexual function). Low sexual function (LSF) was defined as an FSFI overall score of less than 26.55. Distress related to low FSFI score (required for the diagnosis of sexual dysfunction) was not evaluated. Results: The 670 participants had a mean (SD) age of 52.7 (2.6) years. The t-E2 treatment was associated with a significant yet moderate improvement in the FSFI overall score across all time points compared with placebo (average efficacy, 2.6; 95% CI, 1.11-4.10; adjusted P = .002). With o-CEE treatment, there was no significant difference in FSFI overall score compared with placebo (mean efficacy, 1.4; 95% CI, -0.1 to 2.8; adjusted P = .13). There was no difference in FSFI overall score between the t-E2 and o-CEE groups on average across 48 months (adjusted P = .22). In the individual domains of sexual function, t-E2 treatment was associated with a significant increase in mean lubrication (0.61; 95% CI, 0.25-0.97; P = .001) and decreased pain (0.67; 95% CI, 0.25-1.09; P = .002) compared with placebo. Overall, the proportion of women with LSF was significantly lower after t-E2 treatment compared with placebo (67%; 95% CI, 55%-77% vs 76%; 95% CI, 67%-83%; P = .04). For o-CEE there was no significant reduction in the odds of LSF. Conclusions and Relevance: Treatment with t-E2 modestly improved sexual function in early postmenopausal women, but whether it relieved symptoms of distress is not known. Trial Registration: clinicaltrials.gov Identifier: NCT00154180.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, C. B. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278597 · Cited by 6,593
Sexual Dysfunction in the United States: Prevalence and Predictors
Laumann, E. O., Paik, A., & Rosen, R. C. (1999) · JAMA · doi:10.1001/jama.281.6.537 · Cited by 5,119
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores
WIEGEL, M., MESTON, C., & ROSEN, R. (2005) · Journal of Sex & Marital Therapy · doi:10.1080/00926230590475206 · Cited by 2,396
Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy
Davison, S. L., Bell, R., Donath, S., Montalto, J. G., & Davis, S. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0212 · Cited by 998
MESTON, C. M. (2003) · Journal of Sex & Marital Therapy · doi:10.1080/713847100 · Cited by 555
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Burger, H. G., Dudley, E. C., Cui, J., Dennerstein, L., & Hopper, J. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6740 · Cited by 439
Shifren, J. L., Desindes, S., McIlwain, M., Doros, G., & Mazer, N. A. (2007) · Menopause · doi:10.1097/gme.0b013e31803867a · Cited by 89
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“FDA guidance for treatment of genitourinary symptoms related to menopause in the absence of indications for systemic ET suggests the use of low-dose topical vaginal ET.”
InfluentialSelf-citationHormone therapy for postmenopausal women
Pinkerton, J. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1714787 · Cited by 220
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Self-citation
Metadata
- Authors
- Taylor, H. S., Tal, A., Pal, L., Li, F., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Du, W., Hodis, H. N., Lobo, R. A., Manson, J. E., Merriam, G. R., Miller, V. M., Naftolin, F., Neal-Perry, G., Santoro, N. F., & Harman, S. M.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-01
- Volume
- 177
- Issue
- 10
- Pages
- 1471
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2749066814
- Cited by
- 83
- References
- 9
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). https://app.cochat.ai/papers/10.1001/jamainternmed.2017.3877
- The paper
- Taylor, H. S., Tal, A., Pal, L., Li, F., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Du, W., Hodis, H. N., Lobo, R. A., Manson, J. E., Merriam, G. R., Miller, V. M., Naftolin, F., Neal-Perry, G., Santoro, N. F., & Harman, S. M. (2017). Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2017.3877
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.